Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | F13A1 | P00488 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 2/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179002 | 0.91 | TRPV1 (0.66) | TRPV1ALDH1A1LMNAMAPTDRD1 | |
| Hydrochloric Acid SCHEMBL4119472 | 0.88 | TRPV1 (0.63) | TRPV1KDM4EALDH1A1HPGDPTGS1 | |
| SCHEMBL179009 | 0.88 | TRPV1 (0.79) | TRPV1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL3938664 | 0.88 | TRPV1 (0.63) | TRPV1ALDH1A1MAPTSMN1; SMN2DRD1 | |
| SCHEMBL28515325 | 0.88 | KDM4E (0.68) | TRPV1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL179093 | 0.87 | TRPV1 (0.77) | TRPV1ALDH1A1MAPTSMN1; SMN2DRD1 | |
| Hydrochloric Acid SCHEMBL4111160 | 0.87 | TRPV1 (0.62) | TRPV1ALDH1A1MAPTSMN1; SMN2DRD1 | |
| SCHEMBL178999 | 0.87 | TRPV1 (0.69) | TRPV1DRD1ADRB2ADRA2ADRD2 | |
| SCHEMBL8348726 | 0.86 | ADRB2 (0.71) | TRPV1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL179007 | 0.85 | TRPV1 (0.60) | TRPV1KDM4EALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238124-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | THE GENERAL HOSPITAL CORPORATION (US) | 2021-08-05 | — | — | US | disclosed |
| WO-2019204808-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | THE GENERAL HOSPITAL CORPORATION (US) | 2019-10-24 | — | — | WO | disclosed |
| US-8163957-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease | PROTEOTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110172239-A1 | Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease | PROTAMED, INC. | 2011-07-14 | — | — | US | disclosed |
| US-5232923-A | Stimulates production of nerve growth factor; administering for treatment of regressive disorders of the central nervous system | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1993-08-03 | — | — | US | disclosed |
| EP-0333522-A2 | Catechol derivatives and pharmaceutical preparations containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238124-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | AADAC, ACAT2, AANAT | TRPV1 2185/4885KDM4E 1085/4885ALDH1A1 576/4885 |
| US-20110172239-A1 | Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease | IAPP, SNCA, APP | TRPV1 4061/4885KDM4E 3701/4885ALDH1A1 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.